Foghorn Therapeutics Inc. (FHTX) earnings
FHTX earnings moved a median of +1.55% by the close. Quarterly and annual FHTX reports and results, each read against the price at its own news timestamp. Back to the FHTX overview →
21 measured FHTX earnings events.
Where these FHTX earnings landedvs 21 measured FHTX earnings reactions
| Middle 50% of FHTX earnings reactions | -4.40% to +10.08% |
|---|---|
| Median reaction (to close) | +1.55% |
| Measured reactions | 21 |
Point-in-time · zero look-ahead
Half of the 21 FHTX earnings events with a measured close landed between -4.40% and +10.08%; 52% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Foghorn Therapeutics Provides Second Quarter 2026 Financial and Corporate Update | Press release | +0.00% | +10.08% | |
| Form 10-Q Foghorn Therapeutics For: Jun 30 | SEC filing · Form 10-Q | +0.00% | +10.08% | |
| Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update | Press release | -1.50% | -10.26% | |
| Form 10-Q Foghorn Therapeutics For: Mar 31 | SEC filing · Form 10-Q | -1.50% | -10.26% | |
| Form 10-K Foghorn Therapeutics For: Dec 31 | SEC filing · Form 10-K | -2.59% | -12.14% | |
| Foghorn Therapeutics Provides Third Quarter 2025 Financial and Corporate Update | Press release | +2.83% | +12.99% | |
| Form 10-Q Foghorn Therapeutics For: Sep 30 | SEC filing · Form 10-Q | +2.83% | +12.99% | |
| Foghorn Therapeutics Provides Second Quarter 2025 Financial and Corporate Update | Press release | -1.91% | -4.40% | |
| Form 10-Q Foghorn Therapeutics For: Jun 30 | SEC filing · Form 10-Q | -1.91% | -4.40% | |
| Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update | Press release | +0.00% | -4.42% | |
| Form 10-Q Foghorn Therapeutics For: Mar 31 | SEC filing · Form 10-Q | +0.00% | -4.42% | |
| Form 10-K Foghorn Therapeutics For: Dec 31 | SEC filing · Form 10-K | +1.62% | +1.57% | |
| Foghorn Therapeutics Provides Third Quarter 2024 Financial and Corporate Update | Press release | -0.69% | +11.47% | |
| Form 10-Q Foghorn Therapeutics For: Sep 30 | SEC filing · Form 10-Q | -0.69% | +11.47% | |
| Foghorn Therapeutics Provides Second Quarter 2024 Financial and Corporate Update | Press release | +0.00% | +1.55% | |
| Form 10-Q Foghorn Therapeutics For: Jun 30 | SEC filing · Form 10-Q | +0.00% | +1.55% | |
| Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update | Press release | +3.15% | -3.48% | |
| Form 10-Q Foghorn Therapeutics For: Mar 31 | SEC filing · Form 10-Q | +3.15% | -3.48% | |
| Form 10-K Foghorn Therapeutics For: Dec 31 | SEC filing · Form 10-K | -0.95% | -0.44% | |
| Foghorn Therapeutics Provides Third Quarter 2023 Financial and Corporate Update | Press release | -0.79% | +3.41% | |
| Form 10-Q Foghorn Therapeutics For: Sep 30 | SEC filing · Form 10-Q | -0.79% | +3.41% |
Keep exploring
More FHTX: analyst actions → · SEC filings → · FHTX overview →